These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36044718)

  • 1. Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
    Dowlati A; Abbas A; Chan T; Henick B; Wang X; Doshi P; Fu P; Patel J; Kuo F; Chang H; Balli D
    JCO Precis Oncol; 2022 Aug; 6():e2200257. PubMed ID: 36044718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
    Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
    J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset.
    Febres-Aldana CA; Chang JC; Ptashkin R; Wang Y; Gedvilaite E; Baine MK; Travis WD; Ventura K; Bodd F; Yu HA; Quintanal-Villalonga A; Lai WV; Egger JV; Offin M; Ladanyi M; Rudin CM; Rekhtman N
    Clin Cancer Res; 2022 Nov; 28(21):4702-4713. PubMed ID: 35792876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer.
    Wildey G; Shay AM; McColl KS; Yoon S; Shatat MA; Perwez A; Spainhower KB; Kresak AM; Lipka M; Yang M; Behtaj M; Fu P; Alahmadi A; Mneimneh W; Abbas A; Dowlati A
    Mol Cancer Ther; 2023 Feb; 22(2):264-273. PubMed ID: 36399634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
    J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.
    Bhateja P; Chiu M; Wildey G; Lipka MB; Fu P; Yang MCL; Ardeshir-Larijani F; Sharma N; Dowlati A
    Cancer Med; 2019 Apr; 8(4):1459-1466. PubMed ID: 30773851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
    Rudin CM; Balli D; Lai WV; Richards AL; Nguyen E; Egger JV; Choudhury NJ; Sen T; Chow A; Poirier JT; Geese WJ; Hellmann MD; Forslund A
    J Thorac Oncol; 2023 Sep; 18(9):1222-1232. PubMed ID: 37210008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical correlation of extensive-stage small-cell lung cancer genomics.
    Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
    Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
    Perez BA; Kim S; Wang M; Karimi AM; Powell C; Li J; Dilling TJ; Chiappori A; Latifi K; Rose T; Lannon A; MacMillan G; Saller J; Grass GD; Rosenberg S; Gray J; Haura E; Creelan B; Tanvetyanon T; Saltos A; Shafique M; Boyle TA; Schell MJ; Conejo-Garcia JR; Antonia SJ
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):425-435. PubMed ID: 33002543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
    Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC;
    Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508
    [No Abstract]   [Full Text] [Related]  

  • 12. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
    Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
    J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy.
    Jiang Y; Xie J; Cheng Q; Cai Z; Xu K; Lu W; Wang F; Wu X; Song Y; Lv T; Zhan P
    Int Immunopharmacol; 2024 Nov; 141():112901. PubMed ID: 39151386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
    Owonikoko TK; Park K; Govindan R; Ready N; Reck M; Peters S; Dakhil SR; Navarro A; Rodríguez-Cid J; Schenker M; Lee JS; Gutierrez V; Percent I; Morgensztern D; Barrios CH; Greillier L; Baka S; Patel M; Lin WH; Selvaggi G; Baudelet C; Baden J; Pandya D; Doshi P; Kim HR
    J Clin Oncol; 2021 Apr; 39(12):1349-1359. PubMed ID: 33683919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Papillon-Cavanagh S; Doshi P; Dobrin R; Szustakowski J; Walsh AM
    ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32312757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.